Latest News

Stopping weight management medications drives rapid weight regain and metabolic rebound—making long-term treatment key to optimal outcomes.

Tabitha Peterson, PharmD, discusses how teamwork, strategy, and antidoping expertise sharpen patient care and athlete safety.

Build financial confidence by making strategic money decisions all year.

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.

FDA approves secukinumab for adolescents 12 years and older with moderate to severe hidradenitis suppurativa, offering the first IL-17A option and new hope for earlier relief.

FDA expands Arexvy RSV vaccine to at-risk adults 18-49, backed by phase 3b data—what it means for patients and pharmacists.

No FDA-approved oral suspension of valacyclovir currently exists, meaning pharmacies must continue relying on compounded preparations for patients unable to swallow tablets while Hyloris works to resolve the manufacturing issues.

Although the rates of gabapentin use without a prescription were nearly double those of prescribed use, the trends are decreasing over time.

Ashlan J. Kunz Coyne drives innovative research to combat multidrug-resistant infections and enhance patient care.

Rapid RSV testing in pediatrics cuts unnecessary antibiotic use in young children with viral lung infections.

Ongoing measles outbreaks highlight the impacts of reduced vaccination rates and heightened public distrust in health experts.

Biosimilars lower biologic costs and widen access.

Although the overall proportion of female authors in pharmacy publishing exceeds the representation of women in the pharmacy, medical, and pharmaceutical science workforces, women are more likely to be first authors than senior authors.

How to thrive professionally and personally during pharmacy fellowship

The BPS is reviewing a petition from several professional organizations and seeking public comments on creating a new specialty certification focused on animal health.

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Phase 2 trial finds combination therapy resulted in 22% body weight reduction at 72 weeks, with 92% of weight loss attributable to fat mass, addressing concerns about muscle loss with GLP-1 receptor agonists.

Stable HCV E1E2 proteins on self-assembling nanoparticles spark strong mouse antibodies, advancing a long-sought hepatitis C vaccine.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

This case report highlights pharmacists’ collaborative role in optimizing care transitions and diabetes management for a patient newly diagnosed with LADA (latent autoimmune diabetes in adults).